Biomarkers in chimeric antigen receptor T-cell therapy

Biomark Med. 2018 May;12(5):415-418. doi: 10.2217/bmm-2018-0054. Epub 2018 Apr 26.

Authors

Weimin Kong^{1

2

3}, Simon F Lacey^{1

2

3}, Jan Joseph Melenhorst^{1

2

3}, Joseph A Fraietta^{1

2

3}

Affiliations

¹ Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
² Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA.
³ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia 19104, PA, USA.

PMID: 29697279
DOI: 10.2217/bmm-2018-0054

No abstract available

Keywords: CAR; CTL019; Kymriah; T cell; Tisagenlecleucel; biomarker; cancer; cell therapy; immunotherapy; translational medicine.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Animals
Biomarkers / metabolism
Humans
Immunotherapy, Adoptive* / adverse effects
Mice
Receptors, Chimeric Antigen / metabolism*

Substances

Biomarkers
Receptors, Chimeric Antigen

Grants and funding

P01 CA214278/CA/NCI NIH HHS/United States